Inclusion criteria:

        Parts A, B, C, D, F and G:

          -  Patients must be postmenopausal women

          -  Histological diagnosis of breast adenocarcinoma

          -  Locally advanced or metastatic disease

          -  Either primary tumor or any metastatic site to be positive for Estrogen Receptors
             (ER+) and negative for HER2 (HER2-) receptor

          -  Patients previously treated with endocrine therapy for advanced disease: at least 6
             months exposure to endocrine therapy (Patients with early relapse while on adjuvant
             endocrine therapy that was intitiated ≥24 months ago, or who relapsed < 12 months
             after completion of adjuvant endocrine therapy are eligible); in Part D, no more than
             2 prior lines of endocrine therapy are allowed; in Parts F and G, patients must have
             received and progressed on Aromatase Inhibitor (AI) in combination with CDK4/6
             Inhibitor as the first line (1L) treatment for advanced disease prior to receiving the
             study treatment, and not followed by further endocrine therapy for advanced disease
             before entering the study.

          -  Patients previously treated with chemotherapy for advanced disease: no more than 3
             prior chemotherapeutic regimens in Part A, and no more than 1 prior chemotherapeutic
             regimen in Parts B, C, D and F (including Antibody Drug Conjugates)

          -  Measurable lesion

        Exclusion criteria:

          -  Medical history or ongoing gastrointestinal disorders that could affect absorption of
             oral study drugs (including difficulties with swallowing capsules)

          -  Patient with any other cancer (except for adequately treated basal cell or squamous
             cell skin cancer, in situ cervical cancer or any other cancer from which the patient
             has been disease free for >3 years)

          -  Patients with known brain metastases

          -  Treatment with anticancer agents (including investigational drugs) less than 2 weeks
             before first study treatment starts (less than 4 weeks if the anticancer agents were
             antibodies)

          -  Prior treatment with another selective ER down-regulator (SERD), except fulvestrant
             with a washout of at least 6 weeks prior to the first study drug administration. No
             prior fulvestrant (or any other SERD)(Parts F, G).

          -  Inadequate hematological and biochemical lab tests

          -  Patients with Gilbert disease

          -  Treatment with HIV-antiviral, antifungal and antioxidant agents less than 2 weeks
             before study treatment starts

          -  Treatment with strong and moderate cytochrome P450 (CYP) 3A or CYP2C8 inducers within
             2 weeks before first study treatment

          -  Treatment with strong CYP3A inhibitors within 2 weeks before first study treatment
             starts

          -  More than one prior advanced cyclin-dependent kinase (CDK) 4/6 inhibitor based
             therapy.

        Part F and G only:

          -  Patients with current pneumonitis

          -  Prior therapy with chemotherapy (Part G) and therapies that target the
             phosphoinositide 3-kinase (PI3K) axis: mammalian target of rapamycin (mTOR)
             infibitors, AKT inhibitors, PI3K inhibitors (Part F and G)

          -  Patients with Diabetes Mellitus Type-I or uncontrolled Diabetes Mellitus Type-II

          -  History of Severe Cutaneous Reaction (Stevens-Johnson syndrome [SJS], erythema
             multiforme [EM], toxic epidermal necrolysis [TEN], drug reaction with eosinophilia and
             systemic symptoms [DRESS])

          -  Ongoing jaw osteonecrosis

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.